|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Amortization of discount on available-for-sale securities | |||||
| Equity-based compensation expense | |||||
| Depreciation and amortization expense | |||||
| Loss on sale of property and equipment | |||||
| Non-cash lease expense | |||||
| Non-cash acquired in-process research and development | |||||
| Common stock issued as upfront payment for collaboration and license agreement | |||||
| Change in fair value of derivative liabilities | |||||
| Other | |||||
| Changes in operating assets and liabilities: | |||||
| Prepaid expenses and other current and non-current assets | |||||
| Accounts payable | |||||
| Change in operating lease liability | |||||
| Accrued expenses and other current and non-current liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property and equipment | |||||
| Proceeds from sale of property and equipment | |||||
| Proceeds from sales and maturities of available-for-sale securities | |||||
| Purchases of available-for-sale securities | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from issuance of common stock, net of issuance costs | |||||
| Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions | |||||
| Payments of common stock and pre-funded warrants issuance costs in public offering | |||||
| Proceeds from issuance of common stock and pre-funded warrants in private placement | |||||
| Payments of common stock and pre-funded warrants issuance costs in private placement | |||||
| Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions | |||||
| Proceeds from exercises of common stock options | |||||
| Employee stock purchases and withholdings | |||||
| Employee stock purchase plan purchases | |||||
| Payments of principal portion of finance lease obligations | |||||
| Net cash provided by financing activities | |||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | |||||
| Cash, cash equivalents, and restricted cash at end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Operating cash flows for operating leases | |||||
| Operating cash flows for finance leases | |||||
| Financing cash flows for finance leases | |||||
| Supplemental disclosure of non-cash investing, financing, and operating activities: | |||||
| Common Stock Issued As Payment For Developmental Milestone Consideration | |||||
| Right-of-use assets obtained in exchange for operating lease liabilities | |||||
| Decrease in right-of-use asset and lease liability due to lease termination | |||||
| Decrease in property, plant and equipment due to asset exchange | |||||
| Property and equipment purchases included in accounts payable and accruals | |||||
Loading...